Electra Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Active:3
Completed:1
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Electra Therapeutics Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT05556863
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
🇦🇹Medical University of Vienna, Vienna, Austria
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Phase 2
Recruiting
- Conditions
- Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
- Interventions
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Electra Therapeutics Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT05416307
- Locations
- 🇺🇸
University of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
News
No news found